Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:OCGNNASDAQ:PEPGNASDAQ:YMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$1.90+0.5%$2.15$1.29▼$7.85$208.46M1.241.82 million shs998,160 shsOCGNOcugen$0.73+2.9%$0.64$0.52▼$2.06$212.56M3.784.68 million shs2.68 million shsPEPGPepGen$1.53-4.4%$1.73$0.88▼$19.30$50.02M1.42815,995 shs91,085 shsYMABY-mAbs Therapeutics$4.20-0.7%$4.79$3.84▼$17.78$189.92M0.71327,420 shs152,403 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+0.53%+12.50%-16.00%-53.90%-59.79%OCGNOcugen-1.28%+4.86%-11.19%-0.28%-44.53%PEPGPepGen+4.58%+5.26%+8.11%-18.78%-86.59%YMABY-mAbs Therapeutics+3.17%-12.24%-12.06%-30.54%-71.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon2.0469 of 5 stars3.51.00.00.02.71.70.6OCGNOcugen1.0912 of 5 stars3.50.00.00.02.30.00.0PEPGPepGen2.7707 of 5 stars3.23.00.00.02.22.51.3YMABY-mAbs Therapeutics3.6653 of 5 stars4.43.00.00.01.74.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$18.67882.46% UpsideOCGNOcugen 3.00Buy$6.33770.08% UpsidePEPGPepGen 2.33Hold$10.33575.38% UpsideYMABY-mAbs Therapeutics 2.82Moderate Buy$17.40314.29% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, ANNX, OCGN, and YMAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.003/21/2025YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $12.003/6/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/6/2025OCGNOcugenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/5/2025YMABY-mAbs TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $18.003/5/2025YMABY-mAbs TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.003/5/2025YMABY-mAbs TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$11.00 ➝ $7.003/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/3/2025YMABY-mAbs TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$23.002/24/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/13/2025OCGNOcugenChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AOCGNOcugen$4.06M52.42N/AN/A$0.16 per share4.55PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/AYMABY-mAbs Therapeutics$87.69M2.17N/AN/A$2.32 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%5/12/2025 (Estimated)OCGNOcugen-$63.08M-$0.19N/AN/AN/A-532.51%-154.75%-90.79%5/13/2025 (Estimated)PEPGPepGen-$78.63M-$2.84N/AN/AN/AN/A-60.17%-48.88%5/13/2025 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.67N/AN/AN/A-28.22%-24.61%-18.49%5/6/2025 (Estimated)Latest PEPG, ANNX, OCGN, and YMAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025OCGNOcugen-$0.06N/AN/AN/AN/AN/A5/13/2025Q1 2025PEPGPepGen-$0.72N/AN/AN/AN/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30N/AN/AN/AN/AN/A5/6/2025Q1 2025YMABY-mAbs Therapeutics-$0.21N/AN/AN/A$19.97 millionN/A3/5/2025Q4 2024OCGNOcugen-$0.05-$0.05N/A-$0.05$0.30 million$0.76 million3/4/2025Q4 2024YMABY-mAbs Therapeutics-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 million3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/A2/24/2025Q4 2024PEPGPepGen-$0.81-$0.68+$0.13-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18OCGNOcugen0.042.582.58PEPGPepGenN/A8.478.47YMABY-mAbs TherapeuticsN/A3.923.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AOCGNOcugen10.27%PEPGPepGen58.01%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%OCGNOcugen4.29%PEPGPepGen4.60%YMABY-mAbs Therapeutics22.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableOCGNOcugen80292.01 million278.82 millionOptionablePEPGPepGen3032.69 million31.10 millionNot OptionableYMABY-mAbs Therapeutics15045.22 million34.71 millionOptionablePEPG, ANNX, OCGN, and YMAB HeadlinesRecent News About These CompaniesEarnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to DeclineApril 29 at 11:05 AM | zacks.comBoothbay Fund Management LLC Buys 136,264 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)April 29 at 6:24 AM | marketbeat.comY-mAbs Therapeutics announces presentation of PK data of CD38-SADAApril 28 at 12:06 AM | markets.businessinsider.comY-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measuresApril 27 at 7:05 PM | finance.yahoo.comY-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual MeetingApril 27 at 3:00 PM | globenewswire.comBrookline Capital Management Weighs in on YMAB Q1 EarningsApril 27 at 6:29 AM | marketbeat.comY-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platformApril 26 at 8:59 AM | markets.businessinsider.comYMAB Q1 EPS Estimate Reduced by Brookline Capital ManagementApril 26 at 1:17 AM | americanbankingnews.comY-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin LymphomaApril 25, 2025 | globenewswire.comY-mAbs Therapeutics (NASDAQ:YMAB) Downgraded to "Underperform" Rating by Bank of AmericaApril 24, 2025 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Underperform" at Bank of AmericaApril 24, 2025 | americanbankingnews.comY-mAbs Therapeutics downgraded to Underperform from Neutral at BofAApril 23, 2025 | markets.businessinsider.comY-mAbs downgraded to Underperform at BofA on tough near-term setupApril 23, 2025 | markets.businessinsider.comY-mAbs drops as Bank of America downgrades on headwinds to DanyelzaApril 23, 2025 | msn.comWhy Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 7.47%April 23, 2025 | aaii.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateApril 21, 2025 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Rating of "Moderate Buy" from BrokeragesApril 20, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Down 17.6% in MarchApril 20, 2025 | americanbankingnews.comY-mAbs Therapeutics, Inc.April 16, 2025 | cnn.comY-mAbs Therapeutics: A Yawn From The Market Means OpportunityApril 11, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePEPG, ANNX, OCGN, and YMAB Company DescriptionsAnnexon NASDAQ:ANNX$1.90 +0.01 (+0.53%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.01 (-0.79%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Ocugen NASDAQ:OCGN$0.73 +0.02 (+2.85%) Closing price 04:00 PM EasternExtended Trading$0.73 +0.01 (+0.70%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.PepGen NASDAQ:PEPG$1.53 -0.07 (-4.38%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.02 (-0.98%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Y-mAbs Therapeutics NASDAQ:YMAB$4.20 -0.03 (-0.71%) Closing price 04:00 PM EasternExtended Trading$4.10 -0.10 (-2.36%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
